Novel pharmacokinetic behavior of intravenous busulfan in children with thalassemia undergoing hematopoietic stem cell transplantation: A prospective evaluation of pharmacokinetic and pharmacodynamic profile with therapeutic drug monitoring

Blood

Volumn 115, Issue 22, 2010, Pages 4597-4604

  Gaziev, Javid ^a   Nguyen, Laurent ^b   Puozzo, Christian ^b   Mozzi, Alessia Francesca ^a   Casella, Marialuisa ^a   Donnorso, Michela Perrone ^a   Gravina, Paolo ^a   Sodani, Pietro ^a   Marziali, Marco ^a   Isgrò, Antonella ^a   Simone, Maria Domenica ^a   Andreani, Marco ^a   Formosa, Amanda ^c   Testi, Manuela ^a   Federici, Giorgio ^c,d   Bernardini, Sergio ^c,d   Lucarelli, Guido ^a  

^a TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^b INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; GLUTATHIONE TRANSFERASE A1; GLUTATHIONE TRANSFERASE; IMMUNOSUPPRESSIVE AGENT; PRIMER DNA;

ADOLESCENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY WEIGHT; CHILD; CONFUSION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MONITORING; DRUG SAFETY; FEMALE; GENETIC POLYMORPHISM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMORRHAGIC CYSTITIS; HEPATITIS; HUMAN; HYPERBILIRUBINEMIA; IRON OVERLOAD; LIVER INJURY; LIVER VENOOCCLUSIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUROTOXICITY; PHARMACODYNAMICS; PRIORITY JOURNAL; SIDE EFFECT; SOMNOLENCE; STOMATITIS; SURVIVAL RATE; THALASSEMIA; WILD TYPE; ADULT; CLINICAL TRIAL; GENETICS; GENOTYPE; GRAFT SURVIVAL; INFANT; INTRAVENOUS DRUG ADMINISTRATION; METABOLIC CLEARANCE RATE; METABOLISM; NUCLEOTIDE SEQUENCE; PRESCHOOL CHILD; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; BASE SEQUENCE; BUSULFAN; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; DNA PRIMERS; DRUG MONITORING; FEMALE; GENOTYPE; GLUTATHIONE TRANSFERASE; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; INJECTIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; PROSPECTIVE STUDIES; THALASSEMIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77953937672     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-01-265405     Document Type: Article

References (41)

1. Thomas ED, Buckner CD, Sanders JE, et al. Marrow transplantation for thalassemia. Lancet. 1982;2(8292):227-229.
2. Lucarelli G, Galimberti M, Polchi P, et al. Bone marrow transplantation in patients with thalassemia. N Engl J Med. 1990;322(7):417-421. (Pubitemid 20059509)
3. La Nasa G, Giardini C, Argiolu F, et al. Unrelated donor bone marrow transplantation for thalassemia: the effect of extended haplotypes. Blood. 2002;99(12):4350-4356. (Pubitemid 34627200)
4. Pawlowska AB, Blazar BR, Angelucci E, Baronciani D, Shu XO, Bostrom B. Relationship of plasma pharmacokinetics of high-dose oral Busulfan to the outcome of allogeneic bone marrow transplantation in children with thalassemia. Bone Marrow Transplant. 1997;20(11):915-920. (Pubitemid 27510953)
5. Chandy M, Balasubramanian P, Ramachandran SV, et al. Randomized trial of two different conditioning regimens for bone marrow transplantation in thalassemia: the role of Busulfan pharmacokinetics in determining outcome. Bone Marrow Transplant. 2005;36(10):839-845. (Pubitemid 41655608)
6. Li CK, Yuen PMP, Wong R, et al. Busulphan level and early mortality in thalassemia patients after BMT. Bone Marrow Transplant. 1999;23(4):307-310. (Pubitemid 29105952)
7. Grochow LB, Krivit W, Whitely CB, Blazar B. Busulfan disposition in children. Blood. 1990; 75(8):1723-1727.
8. Hassan M, Ljungman P, Bolme P, at al. Busulfan bioavailability. Blood. 1994;84(7):2144-2150.
9. Bleyzac N, Souillet G, Magron P, et al. Improved clinical outcome of pediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of Busulfan dosage regimen. Bone Marrow Transplant. 2001;28(8):743-751. (Pubitemid 33089217)
10. Bolinger AM, Zangwill AB, Slatteri JT, et al. Target dose adjustment of Busulfan in pediatric patients undergoing bone marrow transplantation. Bone Marrow Transplant. 2001;28(11):1013-1018.
11. Vassal G. Pharmacologically-guided dose adjustment of Busulfan in high-dose chemotherapy regimen: rational and pitfalls [review]. Anticancer Res. 1994;14(6):2363-2370.
12. Andersson BS, Thall PF, Madden T, et al. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for iv BuCy2 in chronic myelogenous leukaemia. Biol Blood Marrow Transplant. 2002;8(9):477-485. (Pubitemid 35174821)
13. Leger F, Nguyen L, Puozzo C. Exposure equivalence between IV (0.8 mg/kg) and oral (1 mg/kg) busulfan in adult patients. Eur J Clin Pharmacol. 2009;65(9):903-911.
14. Zwaveling J, Bredius RGM, Cremers SCLM, et al. Intravenous Busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity. Bone Marrow Transplant. 2005;35(1):17-23. (Pubitemid 40090051)
15. Vassal G, Fischer A, Challine D, et al. Busulfan disposition below the age of three: alteration in children with lysosomal storage disease. Blood. 1993;82(3):1030-1034.
16. Wall D, Chan KW, Eider M, et al. Phase II trial of intravenous busulfan (Busulfex) with cyclophosphamide in pediatric allogeneic hematopoietic cell transplantation: pharmacokinetics, toxicity and efficiency. A Pediatric Blood and Marrow Transplant Consortium study [abstract]. Blood. 2000;96(1):Abstract 480.
17. Nguyen L, Fuller D, Lennon S, Leger F, Puozzo C. I.V. Busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation. Bone Marrow Transplant. 2004;33(10):979-987. (Pubitemid 38744783)
18. Vassal G, Michel G, Esperou H, et al. Prospective validation of novel IV Busulfan fixed dosing for pediatric patients to improve therapeutic AUC targeting without drug monitoring. Cancer Chemother Pharmacol. 2008;61(1):113-123. (Pubitemid 47512633)
19. Bertholle-Bonnet V, Bleyzac N, Galambrun C, et al. Influence of underlying disease on Busulphan disposition in pediatric bone marrow transplant recipients: a nonparametric population pharmacokinetic study. Ther Drug Monit. 2007;29(2):177-184. (Pubitemid 46716183)
20. Gibbs JP, Czerwinski M, Slattery JT. Busulfan-glutathione conjugation catalyzed by human liver cytosolic glutathione S-transferases. Cancer Res. 1996;56(16):3678-3681. (Pubitemid 26272012)
21. Johnson L, Orchard PJ, Baker SK, et al. Glutathione S-transferase A1 cenetic variants reduce Busulfan clearance in children undergoing hematopoietic cell transplantation. J Clin Pharmacol. 2008;48:1052-1062.
22. Zwaveling J, Press RR, Bredius RG, et al. Glutathione S-transferase polymorphisms are not associated with population pharmacokinetic parameters of Busulfan in pediatric patients. Ther Drug Monit. 2008;30(4):504-510.
23. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22(6):696-699.
24. Sodani P, Gaziev J, Polchi P, et al. New approach for bone marrow transplantation in patients with class 3 thalassemia aged younger than 17 years. Blood. 2004;104(4):1201-1203.
25. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD. Bone Marrow Transplant. 1995;15(6):825-828.
26. Murdter TE, Coller J, Claviez A, et al. Sensitive and rapid quantification of Busulfan in small plasma volumes by liquid chromatography-electrospray mass spectrometry. Clin Chem. 2001;47(8):1437-1442. (Pubitemid 32678823)
27. dos Reis EO, Vianna-Jorge R, Suarez-Kurtz G, Lima EL, Azevedo DA. Development of a rapid and specific assay for detection of busulfan in human plasma by high-performance liquid chromatography/ electrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom. 2005;19(12):1666-1674.
28. Vaughan WP, Carey D, Perry S, Westfall AO, Salzman DE. A limited sampling strategy for pharmacokinetic directed therapy with intravenous Busulfan. Biol Blood Marrow Transplant. 2002; 8(11):619-624. (Pubitemid 35446753)
29. Dupuis LL, Sibbald C, Schechter T, et al. IV Busulfan dose individualization in children undergoing hematopoietic stem cell transplant: limited sampling strategies. Biol Blood Marrow Transplant. 2008;14(5):576-582. (Pubitemid 351494751)
30. Bernardini S, Bellincampi L, Ballerini S, et al. Glutathione S-transferase P1 *C allelic variant increases susceptibility for late-onset Alzheimer disease: association study and relationship with apolipoprotein E epsilon 4 allele. Clin Chem. 2005;51(6):944-951. (Pubitemid 40740873)
31. Jones RJ, Lee KS, Beschorner WE, et al. Veno-occlusive disease of the liver following bone marrow transplantation. Transplantation. 1987;44(6): 778-783.
32. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
33. R Development Core Team. R: A language and Environment for Statistical Computing. R Foundation for Statistical Computing. http://www. R-project.org. Accessed September 14, 2009.
34. Dix SP, Wingard JR, Mullins RE, et al. Association of Busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant. 1996;17(2):225-230.
35. McCune JS, Gooley T, Gibbs JP, et al. Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant. 2002;30(3): 167-173.
36. McCune JS, Gibbs JP, Slattery JT. Plasma concentration monitoring of Busulfan: does it improve clinical outcome? Clin Pharmacokinet. 2000;39(2): 155-165.
37. Poonkuzhali B, Chandy M, Srivastava A, Dennison D, Krishnamoorthy R. Glutathione S-transferase activity influences Busulfan pharmacokinetics in patients with beta thalassemia major undergoing bone marrow transplantation. Drug Metab Dispos. 2001; 29(3):264-267. (Pubitemid 32179525)
38. Slattery JT, Clift RA, Buckner CD, et al. Graft-rejection and toxicity following bone marrow transplantation in relation to Busulfan pharmacokinetics. Bone Marrow Transplant. 1995;16(4):31-42.
39. Kashyap A, Wingard J, Cagnoni P, et al. Intravenous versus oral Busulfan as part of Busulfan/ cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biol Blood Marrow Transplant. 2002;8(9):493-500.
40. Lee JH, Choi SJ, Lee JH, et al. Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous Busulfan vs oral Busulfan in adults conditioned with Busulfan+cyclophosphamide for allogeneic bone marrow transplantation. Ann Hematol. 2005;84(5):321-330.
41. Hassan M, Ljungman P, Ringden O, et al. The effect of Busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity. Bone Marrow Transplant. 2000;25(9):915-924.